Read this company snapshot
Daily valuation snapshot
NewAmsterdam Pharma Company N.V. Ordinary Shares: source evidence dated 2026-10-09.
- Daily close (USD)
- $21.58
- Market capitalization (USD)
- $2,579,014,421.17
- Price / earnings (TTM)
- Not reported
- Price / book
- 4.08
The source values and product destination above identify the example to inspect.
What business is this, and what does its dated valuation mean?
Check the market day first. P/E uses trailing earnings; book value and market capitalization answer different questions.
Daily valuation dataset and column definitionsOpen the company research view or ask Aurora to reconcile reporting periods, earnings, debt and the figures behind the valuation.
Research NAMS in the app
Open the company research view or ask Aurora to reconcile reporting periods, earnings, debt and the figures behind the valuation.
Research NAMS in the appKeep reporting dates and units beside the answer, and inspect its original citations.
Company overview
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.
Daily valuation snapshot
See the complete daily valuation snapshot
These values come from the daily market snapshot dated 2026-10-09. TTM means trailing twelve months. Use the market date when comparing NAMS with another company.
Scroll sideways to compare all columns. Select a heading to sort.
| Daily close (USD) | $21.58 |
| Market capitalization (USD) | $2,579,014,421.17 |
| Price / earnings (TTM) | Not reported |
| Price / book | 4.08 |
No matching rows. Clear the filter to see all records.
Read NAMS's valuation metrics
Company size
NewAmsterdam Pharma Company N.V. Ordinary Shares's recorded market capitalization is $2,579,014,421.17. It measures the market value of the company's equity, rather than its revenue or cash balance.
Price relative to earnings
P/E compares share price with trailing annual earnings per share. For a company with losses, inspect the earnings figures directly rather than treating a negative multiple as a cheap valuation.
Price relative to book equity
NAMS's recorded price-to-book ratio is 4.08. That compares its market equity value with recorded book equity. Examine its business and balance sheet to understand why those values differ.
Research NewAmsterdam Pharma Company N.V. Ordinary Shares with Aurora
Use the snapshot above to ask a specific question about NAMS. Ask for the report period and the figures behind the explanation, then compare the answer with the company's business description.
Continue the research
Follow NAMS's ownership disclosures to see who filed a transaction or position and when it became public. To turn a research idea into a strategy, define an entry rule and test its dated observations.